The tweet was deleted by the author.
But we saved everything 🙂.
Vir Biotechnology has named David Liu as executive vice president and chief medical officer. The company stated that Liu brings significant experience in immuno-oncology and global regulatory strategies as Vir Biotechnology advances therapies for cancer and chronic Hepatitis Delta.
The appointment marks a strategic leadership move as the company continues to develop pipeline therapies targeting critical disease areas.
View post on X Loading...
In March, Vir Biotechnology named Aziz Sawaf as executive vice president and chief financial officer with oversight of finance, operations, IT, and investor relations, according to company disclosures. The company recently presented expanded Phase 2 data on its oral therapies for chronic Hepatitis Delta at a conference in Denver, as detailed in previous announcements. These developments come as Vir advances its leadership and clinical programs.